US88032L6056 - Common Stock
TENAX THERAPEUTICS INC
NASDAQ:TENX (3/28/2024, 8:00:01 PM)
After market: 4.02 -0.22 (-5.19%)4.24
+0.37 (+9.56%)
Tenax Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Chapel Hill, North Carolina and currently employs 7 full-time employees. Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The company has the rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
TENAX THERAPEUTICS INC
101 Glen Lennox Drive, Suite 300
Chapel Hill NORTH CAROLINA 27560
P: 19198552100
CEO: Anthony DiTonno
Employees: 7
Website: http://www.tenaxthera.com/
TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tenax Therapeutics (NASDAQ:TENX) just reported results for the fourth quarter o...
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with...
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company...
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment...
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded...
Here you can normally see the latest stock twits on TENX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: